This is a report that came out of the AASLD today. Some of you had heard of this before where they did a first of a kind trial using only a polymerase inhibitor and a protease inhibitor. There was no interferon or ribavarin in htis trial. It seems to have some promise. It is way early to say anything conclusive about this but encouraging just the same. This may be a glimpse of the future. below is the news bulletin.
Presented: Tuesday, November 3, 2009, 8:00 am Eastern Time in Boston, MA
ALEXANDRIA, Va. and BOSTON, Nov. 2 /PRNewswire/ -- All approved therapy
regimens to treat patients with hepatitis C are based on interferon, which
must be injected. In this clinical trial to be presented at the annual meeting
of the American Association for the Study of Liver Diseases, researchers
treated patients - both treatment naive and experienced patients - with a
twice daily oral combination therapy of a nucleoside polymerase and protease
inhibitor. The results were significant antiviral potency and sustained viral
reductions. In addition, the therapy appeared safe and well-tolerated. "The
expected better tolerability of these IFN-free combination DAA regimens may
make treatment easier for patients and also allow for patients to be treated
who are unable to take interferon based therapy," said Edward Gane, MD, lead
investigator on this study. "The greater numbers treated and better success
rates should eventually help reduce the future projected burden of end-stage
liver disease for chronic HCV."
The INFORM-1 trial is randomized, double-blind, and placebo controlled. The
oral therapy was administered over a 14-day period, and the antiviral
responses were impressive among all groups. It was reported that the
combination is undergoing further development for treatment of chronic
hepatitis C. "This is the first study to demonstrate that an IFN-free, twice
daily, combination DAA regimen produces similar antiviral activity compared to
triple therapy (SOC plus protease) over 2 weeks of treatment," said Dr. Gane.
"This combination may represent the first IFN-free treatment regimen for both
treatment-naive and previously treated patients with HCV Genotype 1
infection."
These results are very promising in regards of antiviral potency and lack of
resistance development. "From here we will need to explore in a stepwise
fashion if longer treatment will result in persistent viral suppression, clear
all HCV-infected hepatocytes and ultimately lead to a sustained virologic
response (SVR)," said Dr. Gane. He concluded by saying, "as we explore this
new treatment paradigm, we hope to gain a better understanding of the virus
host interaction in HCV, as DAA induced viral suppression in the absence of
extrinsic interferon allows us to study intrinsic interferon responses and
associated biomarkers."
Abstract title:
Combination therapy with a nucleoside polymerase (R7128) and protease
(R7227/ITMN-191) inhibitor in HCV: Safety, pharmacokinetics, and virologic
results from INFORM-1